| Nazwa produktu: |
adriamycyna |
| Synonimy |
13-dihydrodoksorubicyna; 10-((3-amino-2,3,6-trideoksy-alfa-L-lyxo-heksopiranozylo)oksy)-8-(1,2-dihydroksyetylo)-7,8,9,10-tetrahydro-6,8,11-trihydroksy-1-metoksy-5,12-naftecenion; 5,12-naftacenidon, 10-((3-amino-2,3,6-trideoksy-alfa-L-lyxo-heksopiranozylo)oksy)-8-(1,2-dihydroksyetylo)-7,8,9,10-tetrahydro-6,8,11-trihydroksy-1-metoksy-; 3-(1,2-dihydroksyetylo)-3,5,12-trihydroksy-10-metoksy-6,11-diokso-1,2,3,4,6,11-heksahydrotetracen-1-yl 3-amino-2,3,6-trideoksy-L-likso-heksopiranozyd; chlorowodorek (1S,3S)-3-[(1S)-1,2-dihydroksyetylo]-3,5,12-trihydroksy-10-metoksy-6,11-diokso-1,2,3,4,6,11-heksahydrotetracen-1-ylu 3-amino-2,3,6-trideoksy-alfa-L-likso-heksopiranozydu (1:1) |
| Angielska nazwa |
adriamycinol;13-Dihydrodoxorubicin; 10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-; 3-(1,2-dihydroxyethyl)-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoside; (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside hydrochloride (1:1) |
| MF |
C27H32ClNO11 |
| Masie cząsteczkowej |
581.9961 |
| InChI |
InChI=1/C27H31NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,16-,17-,22+,27-;/m0./s1 |
| Nr CAS |
141434-67-5 |
| Struktury molekularnej |
|
| Temperatura wrzenia |
828.7°C at 760 mmHg |
| Temperatura zapłonu |
455°C |
| Ciśnienie pary |
4.26E-29mmHg at 25°C |
| Symbole zagrożenia |
|
| Kody ryzyka |
|
| Bezpieczeństwo opis |
|
|
